MEDI 7219
Alternative Names: MEDI7219Latest Information Update: 07 Sep 2020
At a glance
- Originator MedImmune
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 Aug 2020 Medimmune discontinues a phase I trial in Type 2 diabetes (In volunteers)in United Kingdom (NCT03362593)
- 18 Aug 2020 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in United Kingdom (IV) (AstraZeneca pipeline, August 2020)
- 05 Dec 2017 Preclinical trials in Type-2 diabetes mellitus in USA (IV) (NCT03362593) before December 2017